Details of the Drug

General Information of Drug (ID: DML4BT1)

• Drug Name: Eftilagimod alpha
• Synonyms: IMP321

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 2	[1]
Squamous head and neck cell carcinom	2D60.0	Phase 2	[1]

• Drug Type: Recombinant?protein
• Cross-matching ID: TTD ID: DAL5C7
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

References

• [1] ClinicalTrials.gov (NCT03625323) Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002). U.S. National Institutes of Health.